Overview

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Status:
NOT_YET_RECRUITING

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given separately or together will also be evaluated.

Phase:

PHASE1

Details

Lead Sponsor:

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Treatments:

Atorvastatin
Digoxin
repaglinide
Rosuvastatin Calcium